Free Trial
NYSE:MED

Medifast (MED) Stock Price, News & Analysis

Medifast logo
$11.55 +0.12 (+1.05%)
As of 12:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About Medifast Stock (NYSE:MED)

Advanced

Key Stats

Today's Range
$11.42
▼
$11.62
50-Day Range
$9.73
▼
$13.12
52-Week Range
$9.22
▼
$14.06
Volume
29,164 shs
Average Volume
211,007 shs
Market Capitalization
$129.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Reduce

Company Overview

Medifast, Inc. is a health and wellness company that provides weight-management and healthy-living products and services. Its primary brand, OPTAVIA, offers meal replacements, snacks, supplements and other nutrition products designed to support structured weight-management programs.

The company’s programs combine nutrition products with guidance from independent OPTAVIA Coaches. These coaches provide accountability, support and lifestyle guidance intended to help clients develop healthier eating and activity habits.

Medifast was founded in 1980 and is headquartered in Baltimore, Maryland. The company primarily serves customers in the United States through its direct-to-consumer business model and network of independent coaches.

AI Generated. May Contain Errors.

Medifast Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
38th Percentile Overall Score

MED MarketRank™: 

Medifast scored higher than 38% of companies evaluated by MarketBeat, and ranked 128th out of 166 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Medifast has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for Medifast is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    Medifast has only been the subject of 2 research reports in the past 90 days.

  • Read more about Medifast's stock forecast and price target.
  • Earnings Growth

    Earnings for Medifast are expected to grow in the coming year, from ($1.04) to ($0.47) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Medifast is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Medifast is -4.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Medifast has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Medifast's valuation and earnings.
  • Percentage of Shares Shorted

    17.29% of the float of Medifast has been sold short.
  • Short Interest Ratio / Days to Cover

    Medifast has a short interest ratio ("days to cover") of 20.02, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Medifast has recently decreased by 1.11%, indicating that investor sentiment is improving.
  • Dividend Yield

    Medifast does not currently pay a dividend.

  • Dividend Growth

    Medifast does not have a long track record of dividend growth.

  • News Sentiment

    Medifast has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Consumer Staples companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Medifast this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    1 people have added Medifast to their MarketBeat watchlist in the last 30 days.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $1,197,276.00 in company stock, which represents 0.9300% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Medifast insiders have bought 529.07% more of their company's stock than they have sold. Specifically, they have bought $1,423,576.00 in company stock and sold $226,300.00 in company stock.

  • Percentage Held by Insiders

    3.70% of the stock of Medifast is held by insiders.

  • Percentage Held by Institutions

    95.51% of the stock of Medifast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Medifast's insider trading history.
Receive MED Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MED Stock News Headlines

What Actually Keeps Weight Off After a Weight Loss Program
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
Why Do You Keep Gaining Weight Back After Losing It
Why Weight Loss Plateaus Happen: 5 Metabolic Causes
See More Headlines

MED Stock Analysis - Frequently Asked Questions

Medifast's stock was trading at $10.66 on January 1st, 2026. Since then, MED shares have increased by 8.0% and is now trading at $11.5150.

Medifast Inc (NYSE:MED) announced its quarterly earnings data on Monday, August, 3rd. The specialty retailer reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.65) by $0.37. The specialty retailer had revenue of $76.38 million for the quarter, compared to analysts' expectations of $72.70 million. Medifast had a negative net margin of 8.08% and a negative trailing twelve-month return on equity of 6.69%.
Read the conference call transcript
.

Shares of MED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medifast investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY).

Company Calendar

Last Earnings
8/03/2026
Today
10/09/2026
Next Earnings (Estimated)
11/09/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Personal Care Products
Sub-Industry
Personal Care Products
Current Symbol
NYSE:MED
CIK
910329
Employees
380
Year Founded
1981

Price Target and Rating

High Price Target
$12.00
Low Price Target
$12.00
Potential Upside/Downside
+4.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.33)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.67 million
Net Margins
-8.08%
Pretax Margin
-4.41%
Return on Equity
-6.69%
Return on Assets
-5.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.86
Quick Ratio
4.35

Sales & Book Value

Annual Sales
$385.79 million
Price / Sales
0.33
Cash Flow
$0.42 per share
Price / Cash Flow
27.56
Book Value
$18.10 per share
Price / Book
0.64

Miscellaneous

Outstanding Shares
11,180,000
Free Float
10,767,000
Market Cap
$129.03 million
Optionable
Optionable
Beta
0.68

Social Links

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (NYSE:MED) was last updated on 10/9/2026 by MarketBeat.com Staff.
From Our Partners